TABLE 2.
Synthetic cyclic peptides inhibit ANDV infection
| Target | Sample | % Inhibition bya:
|
|
|---|---|---|---|
| Peptide-bearing phage | Synthetic peptide | ||
| Gn | CMQSAAAHC | 48.88 (44.40) | 59.66 (11.17) |
| Gc | CTVGPTRSC | 57.30 (11.31) | 46.47 (7.61) |
| Gn | CPSNVNNIC | 61.11 (25.41) | 44.14 (10.74) |
| Gn | CEKLHTASC | 43.60 (27.92) | 34.87 (9.26) |
| Gc | CPKLHPGGC | 71.88 (27.11) | 30.95 (7.73)b |
| Gn | CSLHSHKGC | 45.11 (49.81) | 29.79 (9.34) |
| Gc | CPMSQNPTC | 65.60 (13.49) | 18.19 (8.55)b |
| Gn | CKSLGSSQC | 53.90 (13.34) | 18.10 (7.55)b |
| Gn | CNSHSPVHC | 45.40 (28.80) | 15.52 (10.48) |
| Gn | CPAASHPRC | 51.84 (17.09) | 0 (10.72)b |
| Integrin β3 | ReoPro | 80.10 (7.72) | |
| Gn | 6B9/F5 antibody | 42.72 (6.75) | |
| Gc | 6C5/D12 antibody | 31.04 (7.81) | |
a
Standard deviations of the results of at least four experiments are shown in parentheses.
b
Mean percent inhibition between phage and synthetic peptide differs significantly (P < 0.05).